Estée Lauder's Dr.Jart+ Writedown: What a Strategic Exit Actually Buys a Korean Founder
- 1 day ago
- 4 min read
Estée Lauder wrote USD 375 million off Dr.Jart+ in fiscal 2025, then ran a sale process for the brand, took bids, and decided in July 2026 to keep it and shrink the team instead. The company's fiscal 2026 results, published on 19 August 2026, name Dr.Jart+ in exactly two places. This is the clearest public record of what happens to a Korean brand after the exit everyone treats as the finish line.
What did Estée Lauder's fiscal 2026 results actually say?
The Estée Lauder Companies reported net sales up 5% to USD 15.0 billion for the year ended 30 June 2026. Organic sales rose 3%. Fourth-quarter organic growth accelerated to 5%, a fourth consecutive quarter of growth. Adjusted operating margin expanded 320 basis points, to 11.2%. Gross margin reached 75.5%.
"We reignited growth with organic sales rising 3%, driven by the breadth of growth across brands, and achieved significant operating margin expansion," said President and CEO Stéphane de La Faverie.
Breadth across brands. The release names which ones. Fragrance grew 10% organically, led by Le Labo, TOM FORD and KILIAN PARIS. Skin Care rose 4% organically, led by La Mer, The Ordinary and Estée Lauder. Jo Malone London and TOM FORD joined the roster of billion-dollar brands, taking the count to six.
Dr.Jart+ is named in exactly two places in that release. Once in the paragraph listing every brand the company sells. Once in an impairment footnote.
How much did Estée Lauder write off against Dr.Jart+?
USD 375 million, in fiscal 2025.
The footnote is worth reading twice. The company determined that the carrying value of the Dr.Jart+ trademark exceeded its estimated fair value and recorded an USD 83 million trademark impairment. Alongside it sits a USD 292 million impairment against the brand's customer list intangible.
That USD 375 million accounts for the whole "other intangible asset impairments" line for the entire Asia/Pacific region that year. One Korean asset, the full regional figure.
What did Estée Lauder pay for Have & Be Co. in 2019?
In November 2019, Estée Lauder agreed to buy the two-thirds of Have & Be Co. it did not already own, following a minority investment made in December 2015. Have & Be carried a total enterprise value of approximately USD 1.7 billion. It was the company's first acquisition of an Asia-based beauty brand.
Dr.Jart+ was then expected to exceed USD 500 million in net sales for calendar 2019.
Set the two numbers beside each other and the shape of the thing is obvious. What is not obvious, and what the footnote actually explains, is how it happened.
Why did the value disappear?
Not through neglect. Through decisions.
The impairment note records that a decision was made "in the prior year in the reporting unit's operating plan to exit the travel retail channel," and that a revised strategy followed involving "increased direct investment in other areas of the business, including in mainland China, to support the brand's future growth." Growth in key geographies then came in below expectation — specifically, the note says, in mainland China and Korea — and internal forecasts were revised downwards.
Read that as an operator rather than an analyst.
Travel retail was not a side channel for a Korean skincare brand in the late 2010s. For a great many of them it was the demand engine. A new owner looked at it, judged it low-quality revenue, and closed it.
That is a defensible call on its own terms, and plenty of Western portfolio managers made the same one in the same window. But the growth curve the buyer had paid for was generated by that channel. Removing it and redirecting spend into direct mainland China investment was not housekeeping. It produced a different company.
Did Estée Lauder sell Dr.Jart+?
No. It nearly did, and then it did not — and the sellers had no vote in either outcome.
In November 2025, Axios reported that Estée Lauder was exploring a sale of Dr.Jart+, with the brand expected to generate around USD 150 million in 2025 revenue. By June 2026, KED Global reported that The Founders Inc., the Korean company behind Anua, was looking at buying it, with the brand discussed in the market at around USD 130 million.
Then, in July 2026, a leaked internal memo from Stéphane de La Faverie — the contents of which Estée Lauder confirmed to BeautyMatter — said the company would keep it. Too Faced, Smashbox and Dr.Jart+ would all be retained and restructured instead. Dr.Jart+ stays in South Korea with a leaner, more agile team, focused on innovation and selected regions.
That is the complete arc, and it is the part worth sitting with. A Korean brand was bought, revalued, written down, put on the block, priced by the market at under a tenth of its 2019 enterprise value, taken off the block, and shrunk — across six years in which every one of those decisions was made about it and none by it.
What does a strategic exit actually buy?
A strategic acquirer buys a growth curve. It does not buy — and cannot be made to buy — a commitment to keep generating that curve the same way.
Every restructuring programme is a concentration exercise, and Estée Lauder's has been unusually explicit: USD 1.2 billion in annual gross benefits at the high end of the range, a net reduction of approximately 10,000 positions, six billion-dollar brands.
Concentration is how the margin came back. Concentration also means something gets deprioritised, and the likeliest candidate is the asset whose operating logic the buyer understands least.
What should a Korean founder ask before a strategic sale?
None of this is an argument against selling. It is an argument for a narrower question in the room than most Korean sellers ask.
Not what is the multiple, but: which channel decisions survive closing?
Who holds the pricing ladder in Asia travel retail on day one?
What happens to the assumption base if the acquirer decides a channel is dilutive?
Because the honest answer to the last one is now on file, in a footnote, at USD 375 million.
Comments